Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 4/20 | 0.43 |
| ▸ | CCKBR | P32239 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | GRPR | P30550 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661913 | 0.84 | ROCK2 (0.52) | ROCK2ROCK1HPGDSPTPN1PTPN2 | |
| SCHEMBL1661020 | 0.82 | CTSL (0.53) | PTPN1MME | |
| SCHEMBL1660937 | 0.79 | APC (0.52) | CCKBRPTPN1CCKAR | |
| SCHEMBL25626461 | 0.79 | ACE (0.48) | PTPN1PTPN2ACE | |
| SCHEMBL25627547 | 0.78 | ACE (0.48) | PTPN1PTPN2LNPEPERAP2ACE | |
| SCHEMBL1661198 | 0.78 | CTSL (0.57) | PTPN1ACEMME | |
| SCHEMBL1662115 | 0.77 | NPY4R (0.56) | PTPN1PTPN2 | |
| SCHEMBL1660331 | 0.77 | NPY4R (0.58) | PTPN1PTPN2 | |
| SCHEMBL25627552 | 0.77 | OPRD1 (0.51) | ACE | |
| SCHEMBL1660444 | 0.77 | PTPN1 (0.52) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| US-10697019-B2 | Method of diagnosis and prognosis | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3180350-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | Imperial Innovations Ltd (GB) | 2017-06-21 | — | — | EP | disclosed |
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| EP-2702167-B1 | METHODS OF DIAGNOSIS AND PROGNOSIS OF MULTIPLE MYELOMA, BY MEASURING GADD45BETA EXPRESSION | IMP INNOVATIONS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-9518083-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| WO-2016024131-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-02-18 | — | — | WO | disclosed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | disclosed |
| US-8993717-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-20140128330-A1 | METHOD OF DIAGNOSIS AND PROGNOSIS | IMPERIAL INNOVATIONS LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| EP-2702167-A2 | METHOD OF DIAGNOSIS AND PROGNOSIS | Imperial Innovations Limited (GB) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012146940-A2 | METHOD OF DIAGNOSIS AND PROGNOSIS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | ROCK2 1294/4885ROCK1 1694/4885HPGDS 799/4885 |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | ROCK2 3346/4885ROCK1 3733/4885HPGDS 120/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | ROCK2 3346/4885ROCK1 3733/4885HPGDS 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.